Pharmaceuticals

Prescription medicines.

23 brands with a current stake on record.

UPTRAVI
UPTRAVI is an oral and intravenous treatment for pulmonary arterial hypertension. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.
- Controlling stakeJohnson & Johnson
XARELTO
XARELTO is an oral anticoagulant. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and says it was co-developed with Bayer HealthCare AG.
- Controlling stakeJohnson & Johnson
ZYTIGA
ZYTIGA is a treatment for prostate cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and notes loss of exclusivity in the 2025 sales discussion.
- Controlling stakeJohnson & Johnson